These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 22393120)

  • 1. Metabolic switching of BILR 355 in the presence of ritonavir. I. Identifying an unexpected disproportionate human metabolite.
    Li Y; Lai WG; Whitcher-Johnstone A; Busacca CA; Eriksson MC; Lorenz JC; Tweedie DJ
    Drug Metab Dispos; 2012 Jun; 40(6):1122-9. PubMed ID: 22393120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase.
    Li Y; Xu J; Lai WG; Whitcher-Johnstone A; Tweedie DJ
    Drug Metab Dispos; 2012 Jun; 40(6):1130-7. PubMed ID: 22393121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
    Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
    J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
    J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
    Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
    Grubb MF; Diamond S; Christ DD
    Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
    Prakash C; Wang W; O'Connell T; Johnson KA
    Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.
    Li F; Lu J; Ma X
    Drug Metab Dispos; 2012 Jan; 40(1):18-24. PubMed ID: 21953914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
    Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
    Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.
    Daali Y; Ancrenaz V; Bosilkovska M; Dayer P; Desmeules J
    Metabolism; 2011 Nov; 60(11):1584-9. PubMed ID: 21550074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
    Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
    J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.